HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Characteristics and functional outcome of traumatic hyphema without routine administration of epsilon-aminocaproic acid.

AbstractBACKGROUND:
The prevalence of traumatic hyphema as well as the distribution of its severity varies among different patient populations. Treatment recommendations in the literature differ significantly among various published reports. This lack of a uniformly accepted treatment probably reflects the different characteristics of this pathology among the populations investigated and cells for a population-adjusted treatment recommendation.
OBJECTIVES:
To report the characteristics and functional outcome of patients with traumatic hyphema and to discuss possible recommendations regarding the use of epsilon-aminocaproic acid.
METHODS:
A prospective, non-randomized study was conducted in 154 consecutive patients with traumatic hyphema, including data collection of ophthalmic status at various time points, the presence or absence of secondary hemorrhage, and final visual acuity.
RESULTS:
Of the 154 eyes studied over 3 years, nearly 90% had hyphema of grade 1 or less, 5 (3.25%) experienced rebleeding, and 2 (1.3%)--neither of which rebled--needed surgical intervention. None of the four patients who experienced final visual acuity of 6/40 or less suffered rebleeding.
CONCLUSION:
The use of epsilon-aminocaproic acid in the studied population was unjustified and routine use of epsilon-aminocaproic acid in our patient population is probably not indicated. A treatment policy regarding epsilon-aminocaproic acid use should be adjusted to the population being treated.
AuthorsItzchak Beiran, Tamar Talmon, Benjamin Miller
JournalThe Israel Medical Association journal : IMAJ (Isr Med Assoc J) Vol. 4 Issue 11 Pg. 1009-10 (Nov 2002) ISSN: 1565-1088 [Print] Israel
PMID12489492 (Publication Type: Journal Article)
Chemical References
  • Antifibrinolytic Agents
  • Aminocaproic Acid
Topics
  • Adolescent
  • Adult
  • Aminocaproic Acid (therapeutic use)
  • Antifibrinolytic Agents (therapeutic use)
  • Child
  • Eye Hemorrhage (etiology)
  • Humans
  • Hyphema (classification, complications, drug therapy)
  • Prospective Studies
  • Severity of Illness Index
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: